Hormone research in paediatrics
Hormone research in paediatrics
Audio Summaries
Every issue of Hormone research in paediatrics moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Recent summaries
The latest articles summarized from Hormone research in paediatrics.
Post-Menarcheal Height Gain After Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious Puberty.
Nov 20, 2026
This retrospective study of 66 girls with central precocious puberty treated with GnRH agonists examined how much height they gained after menarche and whether timing and skeletal maturity affected this residual growth. Post-menarcheal height gain averaged 5.55 cm and was lower when menarche occurred longer after treatment discontinuation, when menarche came at an older age or at greater height, and when bone age was advanced (>11 years) at treatment start. These findings can help clinicians counsel families about expected menarcheal timing and remaining growth after stopping GnRHa therapy.
JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN WITH TYPE 1 DIABETES: IMPACT OF CURRENT MEDICAL TREATMENT OPTIONS ON ANTHROPOMETRY AND METABOLIC CONTROL.
Nov 20, 2026
This study used Diabetes Patient Follow-up (DPV) registry data from 1995 to 2023 to ask whether children with both type 1 diabetes and juvenile idiopathic arthritis differ in anthropometric, metabolic, and cardiovascular risk profiles from children with type 1 diabetes alone. Comparing 489 children with both conditions to 67,462 with type 1 diabetes only, the authors found that the dual-diagnosis group used insulin pumps, CGM, and automated insulin delivery more often and achieved similar HbA1c levels, with HbA1c improving and BMI and height approaching those of the comparison group in 2020–2023. The authors conclude that glycemic control is comparable despite greater disease burden, but the elevated cardiometabolic risks support the need for tailored, interdisciplinary care.
Experiences of Families Receiving Regular Remote Review of CGM to Provide Targeted Supports: A mixed methods study evaluating a pilot model of care in children with Type 1 Diabetes.
Nov 19, 2026
This mixed-methods study explored how parents of children aged 7–14 with type 1 diabetes experienced a pilot model of care in which clinicians regularly reviewed continuous glucose monitoring (CGM) data and provided remote, targeted support. Surveys (n=15) and interviews (n=9) showed the model was largely acceptable, with most families reporting reassurance, improved wellbeing, better diabetes self-management, and a desire to continue. The authors conclude that families highly value support and communication independent of glycaemic outcomes, which may guide future clinical contacts and trials.
Hybrid Closed-Loop Use Mediates the Relationship Between Social Determinants of Health and Glycemic Outcomes in a Canadian Pediatric Type 1 Diabetes Clinic.
Nov 18, 2026
This retrospective study of 581 children with type 1 diabetes at a Canadian pediatric clinic asked whether hybrid closed-loop (HCL) insulin system use explains the link between social determinants of health (measured by neighborhood deprivation quintiles) and glycemic control. HCL use significantly mediated the associations between residential instability or situational vulnerability and HbA1c, with %TIR results consistent with these findings, but it did not mediate effects related to economic dependency or ethnocultural composition. The authors conclude that expanding access to HCL systems may help reduce some inequities, though parallel interventions are still needed to address disparities more fully.
Hypogonadotropic hypogonadism in Weiss-Kruszka syndrome: a report of two cases.
Nov 18, 2026
This case report describes two unrelated Japanese patients with congenital hypogonadotropic hypogonadism or Kallmann syndrome who each carry a de novo truncating ZNF462 variant, a gene known to cause Weiss-Kruszka syndrome. The authors ask whether ZNF462 defects can cause GnRH deficiency, a endocrine feature not typically emphasized in this neurodevelopmental disorder. They conclude that ZNF462 variants broaden the endocrine spectrum of the syndrome and may contribute to GnRH deficiency through neurodevelopmental and epigenetic mechanisms.
Menarche in Young-Onset Type 1 Diabetes: Data from the Australasian Diabetes Data Network (ADDN) Registry.
Nov 18, 2026
This study used registry data from 601 females with type 1 diabetes across nine Australasian centres to examine what factors are linked to age at menarche (median 12.6 years) and how insulin dose, HbA1c, and BMI change before and after menarche. Later menarche was associated with longer diabetes duration, lower insulin dose per kg, higher HbA1c, and lower BMI SDS. The authors found that insulin requirements rise before menarche and peak around it, while HbA1c and BMI continue rising afterward, suggesting that pubertal metabolic changes extend beyond menarche and should inform anticipatory diabetes care during adolescence.
Psychological care of children, adolescents and young adults with diabetes.
Nov 14, 2026
This 2026 ISPAD consensus guideline updates recommendations for psychological care of children, adolescents, and young adults with diabetes, using a biopsychosocial-spiritual and social ecological framework. It addresses how to integrate routine psychosocial screening (including person-reported outcomes, caregiver assessment, and stepped-care pathways) into diabetes care, and expands coverage to topics such as type 1 diabetes screening and staging, eating disorders, neurodevelopmental conditions, parental mental health, transition to adult care, stigma, and health equity. The authors aim to show how culturally sensitive, person-centered, multidisciplinary psychological support can improve well-being, family support, and overall quality of care across diverse settings.
Current Diabetes Technologies and Everyday School Life of Children and Adolescents with Type 1 Diabetes: Did We Do Our Homework?
Nov 13, 2026
This cross-sectional survey of 775 German parents of school-aged children with type 1 diabetes examined whether automated insulin delivery (AID) use improves school participation and reduces parental burden. Although AID users had lower HbA1c, they still faced participation barriers, and AID use was linked to more school phone calls and early pick-ups, suggesting that schools lack adequate diabetes support for these technologies. The authors conclude that structured, standardized school support adapted to new diabetes technologies is needed to shift the burden away from parents.
Isolated Hyperchlorhidrosis Caused by Novel Biallelic CA12 Variants Mimicking Pseudohypoaldosteronism.
Nov 7, 2026
This case report describes a 5-month-old girl with recurrent hyponatremic dehydration and hyperkalemia that initially mimicked pseudohypoaldosteronism, asking whether isolated hyperchlorhidrosis could explain the presentation when CF and PHA workups were unrevealing. Exome sequencing identified two previously unreported compound heterozygous CA12 missense variants (c.823C>T p.(Arg275Trp) and c.694C>A p.(Pro232Thr)) in trans, confirmed by parental testing, with no pathogenic variants in CFTR or PHA-related genes. The authors conclude that these variants expand the mutational spectrum of CA12-related hyperchlorhidrosis and that this diagnosis should be considered in infants with recurrent salt-wasting when routine testing does not support PHA or CF.
When Less is More: A Physiology-Driven Approach to a 17-Hydroxylase Deficiency Case Series.
Nov 6, 2026
This case series of three adolescent girls with 17-hydroxylase deficiency asks whether supraphysiological glucocorticoid treatment is actually necessary, given that elevated deoxycorticosterone (DOC) and corticosterone can provide glucocorticoid and mineralocorticoid effects. The authors found that physiological hydrocortisone dosing combined with titrated spironolactone normalized blood pressure and potassium without side effects, whereas long-term dexamethasone caused multiple complications. They conclude that physiological hydrocortisone and/or mineralocorticoid receptor antagonist monotherapy can control hypertension and hypokalemia while avoiding glucocorticoid-related harm and adrenal suppression.
